Figure 5: Proposed pathways for short-term absorption of ingested genistein and DHG (A) and daidzein and DHD (B) Kato et al. reported that the phase II metabolites of genistein were substrates of MRP2 and BCRP. BCRP, breast cancer resistance protein; DHG, dihydrogenistein; DHD, dihydrodaidzein; MRP, multidrug resistance associated protein; P-gp, P-glycoprotein.